Brenmiller just announced it has signed a Memorandum of Understanding with India’s largest solar panel manufacturer Waaree Energies to deploy its thermal energy storage projects in India. This announcement marks Brenmiller’s entrance into the Indian market, the world’s second most populous country and fifth largest economy, adding to the Company’s growing global presence including Israel, Europe, and the U.S.
It has been 50 years since the FDA approved a new treatment for advanced primary head and neck cancer. CEL-SCI recently announced progress on the regulatory approval front. Approval for Multikine is being pursued in markets including the U.S., Europe, the United Kingdom, and Canada.
Mobilicom just announced expansion into new geographic markets and its 48th design win – meaning its technologies have been integrated as key components into 48 new autonomous robotics and drone systems that are moving toward commercial scale production.
Pluri recently announced a $4.2 million contract from the U.S. National Institutes of Health to advance the development of its PLX-R18 cell therapy to treat hematopoietic acute radiation syndrome, a deadly disease that can result from nuclear disasters and radiation exposure.
Forbes Magazine named it one of the ‘coolest new cars for 2020’, although entering a crowded electric vehicle space, Electra Meccanica has pulled away from the pack by offering consumers a three wheeled micro-vehicle where passengers ride solo, aptly named, the ‘Solo’. Host Annamaria Stewart discusses the novel concept of single rider utility vehicles, the future of urban transportation, and where the Solo fits into the micro-mobility transportation gap with Paul Rivera, CEO of Canadian car company, Electra Meccanica.
It is estimated that more than 330 million people currently suffer from Dry Eye Syndrome worldwide. Although often misunderstood, the complex disease can even lead to a chronic vision threatening disorder, conjunctivochalasis (CCh). Certain modern day conveniences are thought to be a cause in the increase of the condition, with extended viewing of digital screens, laser eye surgery, exposure to air conditioning and increased life expectancy to blame for the growing incidence. The global dry eye market is currently dominated by three companies: Allergan, Novartis, and Santen, but one company is hoping to shake up this $3.7 billion market with their new prescription eye drops. Noam Danenberg Chief Operating Officer of Wize Pharma, joins the show to shed some light on dry eye syndrome and the company’s approach to treatment.
Oramed Pharmaceuticals Inc. (ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Israel’s Ministry of Health has granted the Company approval to initiate an exploratory clinical study of its oral insulin capsule ORMD-0801 in patients with nonalcoholic steatohepatitis (NASH). The proposed three-month treatment study will assess the effectiveness of ORMD-0801 in reducing liver fat content, inflammation and fibrosis in patients with NASH. Oramed plans on initiating the study in the coming month. “Data from our directed preclinical NASH studies and clinical studies of ORMD-0801 in diabetics has revealed, through exploratory endpoints, that our oral insulin capsule has the ability to reduce inflammation of the liver. Incidence of NASH is rapidly increasing, similar to the rates of increase in diabetes. We look forward to exploring ORMD-0801 as a potential treatment for NASH,” stated Oramed CEO, Nadav Kidron. About Oramed Pharmaceuticals Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, Oramed’s Protein Oral Delivery (PODTM) technology is based on over 30 years of research by top scientists at Jerusalem’s Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801). The Company completed multiple Phase II clinical trials under an Investigational New Drug application with the U.S. Food and Drug Administration. In addition, Oramed is developing an oral GLP-1 analog capsule (ORMD-0901).
Pluristem has announced its pivotal Phase III clinical trial to treat critical limb ischemia received clearance from regulatory authorities in the United States, United Kingdom and Germany. Based on these clearances, the Company expects to begin enrolling patients in this study in the coming months.
Pluristem’s PLX-PAD cells will be evaluated in a double blind, randomized, placebo controlled trial in 250 patients.
The global market for treating critical limb ischemia is $12 billion globally. 1.7 million patients who live in world’s largest and most advanced pharmaceutical markets suffer from this limb-threatening and life-threatening disease. This number is expected to top 2 million in the next five years.
Pluristem’s critical limb ischemia program has been selected by the European Medicines Agency for its Adaptive Pathways pilot project. This allows for faster marketing approval in Europe after a single pivotal Phase III trial.
In the current Phase III trial, an interim analysis of data will be made for the first 125 patients, potentially leading to early marketing approval in Europe. Full enrollment is to be completed as planned to pursue full marketing approval in the U.S.
Regenerative medicines like PLX cells will have tremendous benefits on healthcare economics based on their efficacy and their non-invasive nature.
Can-Fite has reported that it is commencing patient recruitment in its global, pivotal Phase III trial of its lead drug candidate Piclidenoson in the treatment of rheumatoid arthritis. The study, titled ACRobat, will enroll 500 patients in Europe, Israel and Canada.
The company reported drug supplies for trial have been manufactured and are ready for administration. The trial will have an estimated cost of $5 million, a modest cost when considering the global market for rheumatoid arthritis drugs is currently $38.5 billion.
Can-Fite’s drug is being developed as a first line therapy and replacement for the current standard of care, Methotrexate. Methotrexate is the most widely used drug for rheumatoid arthritis.
90% of rheumatoid arthritis patients receive Methotrexate at some point in their disease, but 40-50% of patients stop taking it after five years, due to its serious side-effects.
Over 1,000 patients have been safely treated with Piclidenoson, which has shown no series side effects and has proven to be safe. Piclidenoson can offer a superior alternative to Methotrexate for patients who need a safe and effective drug that can be taken long term.
